Por favor, use este identificador para citar o enlazar este ítem:
http://sgc.anlis.gob.ar/handle/123456789/1428
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Duschak, Vilma G | es |
dc.date.accessioned | 2019-12-04T18:54:21Z | - |
dc.date.available | 2019-12-04T18:54:21Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2212-4071 | - |
dc.identifier.uri | http://sgc.anlis.gob.ar/handle/123456789/1428 | - |
dc.description | Fil: Duschak, Vilma G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina. | es |
dc.description.abstract | The American trypanosomiasis, Chagas disease, is a parasitic infection typically spread by triatomine vectors affecting millions of people all over Latin America. Existing chemotherapy is centered on the nitroaromatic compounds benznidazole and nifurtimox that provide unsatisfactory results and substantial side effects. So, the finding and exploration of novel ways to challenge this neglected disease is a main priority. | es |
dc.language.iso | en | es |
dc.publisher | Bentham Science Publishers | es |
dc.relation.ispartof | Recent patents on anti-infective drug discovery | es |
dc.rights | Closed Access | - |
dc.source | Recent patents on anti-infective drug discovery 2016;11(2):74-173. | - |
dc.subject | Trypanosoma cruzi | es |
dc.subject | Enfermedad de Chagas | es |
dc.subject | Patente | es |
dc.title | Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.2174/1574891X11666161024165304 | - |
anlis.essnrd | 1 | - |
item.fulltext | No Fulltext | - |
item.openairetype | Artículo | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | Publicaciones INP |
Visualizaciones de página(s)
89
comprobado en 15-ago-2025
Google ScholarTM
Consultar
Altmetric
Altmetric
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.